SCHOLAR ROCK HOLDING CORP(NASDAQ:SRRK) stock News

SRRK Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill - Mentions: SLE CPSH SAVA RELI ...

Curious about the stocks that are showing activity after the closing bell on Monday?

12 days ago - By: Benzinga - Mentions: CRS BB SKYT ASM ...

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday

15 days ago - By: Benzinga - Mentions: REGN NVS

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

15 days ago - By: Stocktwits - Mentions: VFMO EAOR

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

15 days ago - By: Investor's Business Daily - Mentions: NVO

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

15 days ago - By: Scholar Rock

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

23 days ago - By: The Motley Fool

Why Scholar Rock Stock Bounced Higher on Monday

26 days ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Yahoo Finance

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

2 months ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: REGN LLY VERU

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

2 months ago - By: Scholar Rock

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

2 months ago - By: Yahoo Finance

Why Scholar Rock Stock Wilted on Wednesday

2 months ago - By: The Motley Fool

Scholar Rock (SRRK) Q2 Loss Widens 63%

2 months ago - By: Scholar Rock

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

3 months ago - By: Scholar Rock

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

3 months ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Scholar Rock

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

4 months ago - By: Yahoo Finance

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

4 months ago - By: Stocktwits - Mentions: REGN VTI LLY COIN

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

4 months ago - By: Scholar Rock

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

4 months ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Stocktwits - Mentions: AKRO VTI PFE LLY ...

SCHOLAR ROCK HOLDING CORP (SRRK) Stock News

SRRK Latest News, Press Relases and Analysis

Curious about the stocks that are showing activity after the closing bell on Monday?

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Why Scholar Rock Stock Bounced Higher on Monday

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Why Scholar Rock Stock Wilted on Wednesday

Scholar Rock (SRRK) Q2 Loss Widens 63%

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased